Novartis, Cephalon Disease-Modifying Parkinson's Drugs Near Late-Stage Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis' TCH-346 is slated to enter Phase III in the second half of the year; Cephalon/Lundbeck's CEP-1347 is in Phase II/III. Both drugs claim inhibition of neuronal cell death as the primary mechanism, but will need long-term trials for disease-modification claim.